Basel Medical Finalizes $7.98M Unit Offering at $1.33 — Zero-Cash Warrants Could Add 6M Shares
BMGL sits 43% above its 52-week low of $2.56 on light trading volume (0.2× avg).
Summary
Basel Medical Group finalized a 6-million-unit offering at US$1.33 per unit, raising about US$7.28 million net. The attached common warrants include a zero-cash exercise option that could add 6 million more shares with no additional cash, making the deal highly dilutive.
Key Events · Financing and Capital Events · BMGL
-
6M-Unit Offering Finalized at $1.33
Final prospectus makes effective a 6,000,000-unit offering at US$1.33 per unit for gross proceeds of US$7.98 million. Each unit includes one ordinary share (or pre-funded warrant) and one common warrant.
-
Zero-Cash Warrants Add 6M More Shares
Common warrants are exercisable at 110% of the unit price (US$1.463) and include a zero-cash exercise option. If all 6,000,000 warrants are exercised on a zero-cash basis, 6,000,000 additional shares are issued with no additional cash to the company.
-
Net Proceeds of $7.28M After Fees
After a 6.0% placement agent fee (US$478,800), US$60,000 expense allowance, and US$165,004 other estimated expenses, net proceeds are approximately US$7.28 million, earmarked for working capital and M&A.
-
Extreme Dilution vs 1.58M Shares Outstanding
1,582,111 shares were outstanding before the offering. Full exercise of all units and warrants would bring the total to 13,582,111 shares — an increase of roughly 4.8x. The offering price of US$1.33 is a 59% discount to the October 7, 2026 closing price of US$3.28 stated in the filing.
Analysis · BMGL · Industrial Applications And Services
The final prospectus makes effective a 6-million-unit offering priced at US$1.33 per unit, raising approximately US$7.28 million net after a 6% placement agent fee. The deal is highly dilutive: 6 million ordinary shares (or pre-funded warrants) are issued immediately, and the attached common warrants carry a zero-cash exercise option that could add another 6 million shares with no additional proceeds to the company. Against 1,582,111 shares outstanding before the offering, this represents a roughly 4.8x increase in the share count if all units and warrants are fully exercised. The offering price of US$1.33 is a 59% discount to the October 7, 2026 closing price of US$3.28 stated in the filing, and the company itself warns Nasdaq may halt or delist the stock due to the dilutive warrant structure. This follows a 1-for-12 reverse split in June 2026 to regain Nasdaq's $1 minimum bid compliance, and comes amid a pending securities class action and recent board turnover. The capital is earmarked for working capital and M&A, but the terms reflect a company raising cash under significant distress.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BMGL was trading at $3.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $2.56 to $21.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.